Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07029737 2026-05-07

SOUND-MCL

55 enrolled

Lymphoma, Mantle-Cell

NCT04657094 2026-05-06

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Classical hematologyLymphoidOther hematologic neoplasm

4 enrolled 7 charts

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02029443 2026-05-05

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Phase 1/2 Active not recruiting

306 enrolled 26 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04115631 2026-05-05

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

360 enrolled

Lymphoma, Mantle-Cell

NCT04978584 2026-05-05

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05952024 2026-05-05

ACRUE

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04546620 2026-04-30

REMoDL-A

453 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT05557695 2026-04-23

EPIC

Recruiting

350 enrolled

Leukemia, B-Cell

NCT06205498 2026-04-23

ARISE

Active not recruiting

151 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03623373 2026-04-21

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 13 charts

Phase 1 Active not recruiting

Lymphoma, Mantle-Cell

NCT02717624 2026-04-20

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

72 enrolled

Phase 1 Active not recruiting

Lymphoma, Mantle-Cell

NCT03328273 2026-04-20

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

12 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03932331 2026-04-20

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04189757 2026-04-16

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

9 enrolled

Lymphoma, Mantle-Cell

NCT04169737 2026-04-14

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-04-13

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2026-04-09

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 3 Recruiting

170 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

26 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04722172 2026-04-06

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Phase 1/2 Active not recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02586857 2026-03-25

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

24 enrolled 10 charts

CNSLymphoidOther hematologic neoplasm

Glioblastoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02717611 2026-03-25

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

60 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02180724 2026-03-20

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT05256641 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Phase 1/2 Recruiting

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

29 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03946878 2026-02-17

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

32 enrolled

Lymphoma, Mantle-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

49 enrolled

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07377578 2026-02-06

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3 Recruiting

394 enrolled